123 related articles for article (PubMed ID: 31545520)
1. Severe toxic effects of low-dose methotrexate treatment for placenta accreta in a patient with methylenetetrahydrofolate reductase mutations.
Tan Z; Liu W; Guo H; Hu K; Zhao R
J Clin Pharm Ther; 2020 Feb; 45(1):214-217. PubMed ID: 31545520
[TBL] [Abstract][Full Text] [Related]
2. [Ulcerative stomatitis as clinical clue to inadvertent methotrexate overdose].
Bauer J; Fartasch M; Schuler G; Schell H
Hautarzt; 1999 Sep; 50(9):670-3. PubMed ID: 10501685
[TBL] [Abstract][Full Text] [Related]
3. Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Yu H; Wang W; Liang H; Wang K; Ling B
Front Med (Lausanne); 2021; 8():738315. PubMed ID: 34869432
[No Abstract] [Full Text] [Related]
4. Genetics of high-dose methotrexate-induced oral mucositis: current perspectives.
Heil SG
Pharmacogenomics; 2019 Jun; 20(9):621-623. PubMed ID: 31250729
[No Abstract] [Full Text] [Related]
5. Oral effects of low-dose methotrexate treatment.
Kalantzis A; Marshman Z; Falconer DT; Morgan PR; Odell EW
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Jul; 100(1):52-62. PubMed ID: 15953917
[TBL] [Abstract][Full Text] [Related]
6. High-Dose Methotrexate Treatment in a Breastfeeding Mother with Placenta Accreta: A Case Report.
Baker T; Datta P; Rewers-Felkins K; Hale TW
Breastfeed Med; 2018; 13(6):450-452. PubMed ID: 29985651
[TBL] [Abstract][Full Text] [Related]
7. Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival.
Gemmati D; Ongaro A; Tognazzo S; Catozzi L; Federici F; Mauro E; Della Porta M; Campioni D; Bardi A; Gilli G; Pellati A; Caruso A; Scapoli GL; De Mattei M
Haematologica; 2007 Apr; 92(4):478-85. PubMed ID: 17488658
[TBL] [Abstract][Full Text] [Related]
8. Oral mucositis in patients receiving low-dose methotrexate therapy for rheumatoid arthritis: report of 2 cases and literature review.
Troeltzsch M; von Blohn G; Kriegelstein S; Woodlock T; Gassling V; Berndt R; Troeltzsch M
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 May; 115(5):e28-33. PubMed ID: 23601229
[TBL] [Abstract][Full Text] [Related]
9. The effect of folinic acid on methylenetetrahydrofolate reductase polymorphisms in methotrexate-treated allogeneic hematopoietic stem cell transplants.
Murphy NM; Diviney M; Szer J; Bardy P; Grigg A; Hoyt R; King-Kallimanis B; Holdsworth R; McCluskey J; Tait BD
Biol Blood Marrow Transplant; 2012 May; 18(5):722-30. PubMed ID: 21920473
[TBL] [Abstract][Full Text] [Related]
10. Conservative management of placenta accreta and unruptured interstitial cornual pregnancy using methotrexate.
Lalchandani S; Geary M; O'Herlihy C; Sheil O
Eur J Obstet Gynecol Reprod Biol; 2003 Mar; 107(1):96-7. PubMed ID: 12593905
[TBL] [Abstract][Full Text] [Related]
11. Placenta accreta and methotrexate therapy: three case reports.
Mussalli GM; Shah J; Berck DJ; Elimian A; Tejani N; Manning FA
J Perinatol; 2000; 20(5):331-4. PubMed ID: 10920795
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate-induced oral mucositis and salivary methotrexate concentrations.
Oliff A; Bleyer WA; Poplack DG
Cancer Chemother Pharmacol; 1979; 2(3):225-6. PubMed ID: 313282
[TBL] [Abstract][Full Text] [Related]
13. The effect of leucovorin rescue therapy on methotrexate-induced oral mucositis in the treatment of paediatric ALL: A systematic review.
Van der Beek JN; Oosterom N; Pieters R; de Jonge R; van den Heuvel-Eibrink MM; Heil SG
Crit Rev Oncol Hematol; 2019 Oct; 142():1-8. PubMed ID: 31323533
[TBL] [Abstract][Full Text] [Related]
14. Severe renal toxicity due to intermediate-dose methotrexate.
Stark AN; Jackson G; Carey PJ; Arfeen S; Proctor SJ
Cancer Chemother Pharmacol; 1989; 24(4):243-5. PubMed ID: 2546688
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate for placenta accreta spectrum disorders: Is it needed?
Matsubara S; Takahashi H; Takei Y; Imai Y
J Clin Pharm Ther; 2020 Apr; 45(2):399-400. PubMed ID: 32023348
[No Abstract] [Full Text] [Related]
16. Managing reduced methotrexate clearance in a patient with a heterozygous methylenetetrahydrofolate reductase gene polymorphism.
Gammon DC; Bhatt MS; Patel B; Anderson M; Van Horn A; Glantz MJ
J Oncol Pharm Pract; 2008 Sep; 14(3):153-6. PubMed ID: 18719070
[TBL] [Abstract][Full Text] [Related]
17. Adverse drug reaction to methotrexate: pharmacogenetic origin.
Przekop PR; Tulgan H; Przekop AA; Glantz M
J Am Osteopath Assoc; 2006 Dec; 106(12):706-7. PubMed ID: 17242415
[TBL] [Abstract][Full Text] [Related]
18. Medical treatment of placenta accreta with methotrexate.
Arulkumaran S; Ng CS; Ingemarsson I; Ratnam SS
Acta Obstet Gynecol Scand; 1986; 65(3):285-6. PubMed ID: 3739639
[TBL] [Abstract][Full Text] [Related]
19. [Case report: seventeen year old primipara with placenta increta, treated with methotrexate].
Arnadottir BT; Hardardóttir H; Marvinsdóttir B
Laeknabladid; 2008 Jul; 94(7-8):549-52. PubMed ID: 18591730
[TBL] [Abstract][Full Text] [Related]
20. Conservative management of morbidly adherant placenta - a case report and review of literature.
Khan M; Sachdeva P; Arora R; Bhasin S
Placenta; 2013 Oct; 34(10):963-6. PubMed ID: 23937959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
